Battle Card: Paul Edick Joins Vistagen – Sales Trigger
Paul Edick joins Vistagen’s board. Governance & reg advisory needs spiking. Dial now. Fill pipeline. Boost commission.
Published on
Do not index
Do not index
🚀 Battle Card: Vistagen
Quick trigger:
👤 Decision Maker in the News
- Paul Edick, Board Member (Board of Directors) · 🔗 LinkedIn
💡 Why It Matters
- Paul’s appointment brings deep board-level expertise to de-risk late-stage clinical and market-entry pathways. As a Vistagen sales trigger, this move signals urgent strategic advisory needs. → Source
🎯 Core Pain Point
- Navigating late-stage clinical development & regulatory hurdles
- Scaling commercialization strategy for novel intranasal therapies
💰 What to Pitch
- Primary: Governance & strategic advisory services → strengthen board oversight and growth planning
- Expansion: Regulatory and commercialization support → accelerate FDA submissions and go-to-market readiness
🗺️ Quick Context
- HQ: South San Francisco, CA
- Employees: ≈ 100
- Rev: ≈ $25 M
- Website: vistagen.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Vistagen’s business.
- IQVIA — CRO
- Unique edge: Vast global clinical trial network
- Evaluated by Chief Clinical Officer for trial execution
- Parexel — CRO / Regulatory
- Unique edge: Deep FDA submission expertise
- Evaluated by VP Regulatory Affairs for approval strategy
- Deloitte Life Sciences — Regulatory & Advisory
- Unique edge: End-to-end governance and compliance
- Evaluated by CFO & Chair for board effectiveness
- PwC Health Research Institute — Board Advisory
- Unique edge: Biopharma governance frameworks
- Evaluated by Compensation Committee for strategic oversight
✅ Do-Now Checklist
Connect with Paul Edick on LinkedIn (link above)
Leverage this Vistagen sales trigger to open dialogues on advisory services
Generate email + DM with the Copy-My-Prompt block (Step 7) and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get Vistagen sales trigger intel like this daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑Governance & strategic advisory services❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Paul
COMPANY = Vistagen
DEPT = Board of Directors
SIZE = ≈ TBD
BOTTLENECK = Navigating late-stage clinical development & regulatory hurdles
EVENT = Appoints Paul Edick to its Board of Directors
DETAIL = Vistagen Appoints Paul Edick to its Board of Directors
PAIN = Navigating late-stage clinical development & regulatory hurdles
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251029053793&div=41152219
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ TBD
REV_EST = ≈ TBD
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ TBD-person Board of Directors
Paul—noticed your Board of Directors team is ≈ TBD.
That’s when Navigating late-stage clinical development & regulatory hurdles slows growth.
We helped ≈ TBD fix this with Governance & strategic advisory services.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about Vistagen Appoints Paul Edick to its Board of Directors — Navigating late-stage clinical development & regulatory hurdles.
Governance & strategic advisory services. ≈ TBD.
Quick chat?